(Total Views: 841)
Posted On: 08/05/2020 2:29:33 PM
Post# of 153886
Lenzilumab changed primary endpoint.
From mortality/ mech vent to TTCR
They had an interim planned, no wonder they didn't talk about it during cc. This was the outcome.
https://clinicaltrials.gov/ct2/history/NCT043...udyPageTop
From mortality/ mech vent to TTCR
They had an interim planned, no wonder they didn't talk about it during cc. This was the outcome.
https://clinicaltrials.gov/ct2/history/NCT043...udyPageTop
(9)
(0)
